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Mitogen-activated protein kinase (MAPK) cascades propagate a variety of cellular activities 1 . Processive relay of signals through RAF-MEK-ERK modulates cell growth and proliferation 2, 3 . Signalling through this ERK cascade is frequently amplified in cancers, and drugs such as sorafenib (which is prescribed to treat renal and hepatic carcinomas) and PLX4720 (which targets melanomas) inhibit RAF kinases 4, 5 . Natural factors that influence ERK1/2 signalling include the second messenger cyclic AMP 6, 7 . However, the mechanisms underlying this cascade have been difficult to elucidate. We demonstrate that the A-kinase-anchoring protein AKAP-Lbc and the scaffolding protein kinase suppressor of Ras (KSR-1) form the core of a signalling network that efficiently relay signals from RAF, through MEK, and on to ERK1/2. AKAP-Lbc functions as an enhancer of ERK signalling by securing RAF in the vicinity of MEK1 and synchronizing protein kinase A (PKA)-mediated phosphorylation of Ser 838 on KSR-1. This offers mechanistic insight into cAMP-responsive control of ERK signalling events.
ERK cascades couple signals from growth factors to cell proliferation through mobilization of the GTPase Ras. Active Ras stimulates RAF kinase, which in turn phosphorylates and activates MEK. This intermediary enzyme relays the signal by phosphorylating the terminal kinase ERK, which as an effector enzyme then acts on a range of downstream targets. Interest in this signalling pathway has been prompted by clinical evidence that activating mutations in Ras are found in 20-25% of all human tumours 8 . Second messengers, such as cAMP, can alter signalling through this pathway 6, 7 . However, the mechanism of cAMP action has been challenging to unravel and engenders controversy 9 . Depending on cell type, cAMP positively or negatively controls ERK1/2 activity. Furthermore, cAMP can function through protein kinase A (PKA)-mediated phosphorylation or through the mobilization of guanine nucleotide exchange factors (Epacs) for the Ras-like small GTPases Rap1 and Rap2 (refs 10, 11) . As A-kinase anchoring proteins (AKAPs) compartmentalize PKA and Epacs 12 , we hypothesized that AKAPs could contribute to the modulation of the ERK cascade.
AKAP-Lbc functions as a guanine nucleotide exchange factor for small GTPases and as a kinase-anchoring protein 13, 14 . We performed a proteomic screen for binding partners that could affect ERK1/2 signalling. Lysates from HEK293 cells expressing epitope-tagged (Flag) AKAP-Lbc were incubated with anti-Flag antibodies, immunoprecipitated complexes were isolated and separated by SDS-PAGE and associated proteins were identified by tandem (MS/MS) mass spectrometry (Fig. 1a) . Detection of peptides from AKAP-Lbc and regulatory (RII) and catalytic subunits of PKA (PKAc) were used as internal controls. Peptides from KSR-1, a scaffolding protein for members of the RAF-MEK-ERK cascade 15 , were also identified (Fig. 1a) . This protein-protein interaction was validated in HEK293 cells when recombinant KSR-1 was detected in AKAP-Lbc immunoprecipitated complexes (Fig. 1b) . NIH3T3 fibroblasts endogenously express AKAPLbc and KSR-1. Accordingly, native AKAP-Lbc was co-purified in complex with haemagglutinin (HA)-tagged KSR-1 from the lysates of NIH3T3 fibroblasts expressing HA-KSR-1 (Fig. 1c) , and the native proteins were found to interact when AKAP-Lbc was immunoprecipitated from the lysates of NIH3T3 cells (Fig. 1d) . KSR-1 immunoprecipitated complexes also contained both RII and C subunits of PKA (Fig. 1e) . Next, mapping studies were used to define the interactive surfaces on both AKAP-Lbc and KSR-1 ( Fig. 1f-j) . Binding of KSR-1 to a family of immobilized GST-AKAP-Lbc fragments detected direct interaction with a central portion of AKAP-Lbc (residues 1388-1922; Fig. 1g, h) . Reciprocal experiments demonstrated that AKAP-Lbc interacts with the 331 carboxy-terminal residues of KSR-1 (Fig. 1i, j) . We wanted to investigate how AKAP-Lbc affects KSR-1 function further, especially because cAMP exerts pleiotropic effects on the ERK cascade 11 . Dynamic changes in ERK activity were measured with a genetically encoded fluorescence based Erk-kinase-activity reporter (EKAR) 16 . Phosphorylation of a consensus MAPK-target sequence in the reporter promotes Förster resonance energy transfer (FRET). Changes in the (Fig. 1k) . The EKAR signal was detected within 4.3 ± 0.6 min on treatment of control HEK293 cells with epidermal growth factor (EGF; n = 38; Figs 1l; bottom, 1m; open squares). Importantly, the rate of this response was increased 1.81-fold in cells that co-express AKAP-Lbc with EKAR (Figs 1l; top, 1m; black circles). UO1026, a selective MEK inhibitor, suppressed the EKAR response (Figs 1l, m) . Thus, AKAP-Lbc augments signal transmission through the ERK cascade.
The RAF kinases (A-Raf, B-Raf and C-Raf) relay intracellular signals from the proto-oncogene Ras to activate the ERK1/2 cascade 17 . RAF selectively targets MEK, the next kinase in the chain. Although RAF is recruited into the KSR-1-MEK-ERK scaffold on growth-factor stimulation, 18 we hypothesized that additional mechanisms might maintain RAF in proximity to its substrate, MEK. Therefore, we tested if RAF kinases interact with AKAP-Lbc. Initially, we investigated B-Raf binding in HEK293 cells expressing epitope (Flag)-tagged B-Raf and detected complexes by immunoprecipitation (Fig. 2a) . Native AKAPLbc-B-Raf complexes were also isolated from NIH3T3 cells (Fig. 2b) , and AKAP-Lbc was found to associate with C-Raf or an oncogenic B-Raf V600E mutant ( Supplementary Information, Fig. S1 ). Recombinant in vitro-translated B-Raf was used to screen GST-AKAP-Lbc fragments for direct protein-protein interactions (Fig. 2c, d ). GST pulldowns and immunoblot analysis revealed three RAF-binding fragments in the C-terminal portion of AKAP-Lbc (Fig. 2d) , suggesting that RAF contacts multiple sites on the anchoring protein. The proximity of these regions to the KSR-1 binding site raised the possibility that KSR-1 and AKAP-Lbc could function cooperatively to recruit RAF. This concept was supported by data indicating that co-expression of B-Raf, KSR-1 and AKAP-Lbc augments formation of a ternary complex ( Supplementary  Information, Fig. S2a ).
Immune-complex kinase assays using inactive MEK1 as a substrate demonstrated that AKAP-Lbc anchors active B-Raf (Fig. 2e) . Quantification of phosphorylated MEK indicated a 10.4 ± 0.5-fold (n = 4) enrichment of AKAP-Lbc-associated B-Raf activity when compared with controls ( Fig. 2e, bottom) . Supplementary experiments confirmed the specificity of this assay ( Supplementary Information,  Fig. S2b ). These results suggest that AKAP-Lbc compartmentalizes RAF in proximity to its substrate. This was supported by experiments whereby co-expression of KSR-1 with AKAP-Lbc enriched the copurification of MEK1 in AKAP-Lbc-immunoprecipitated complexes (Fig. 2f ). These data suggest that AKAP-Lbc and KSR-1 form the core of a signalling network to efficiently relay signals from RAF, through MEK, and on to ERK1/2. 1  503  504  1000  1001  1387  1388  1922  2337  2337  1923  2817 Raf activity (A.U.) To test this hypothesis, we first investigated whether varying the cellular levels of this anchoring protein influenced the basal activation state of MEK, as AKAP-Lbc constitutively binds B-Raf (Fig. 2) . Antibodies against phosphorylated MEK1 were used to monitor MEK activation in HEK293 cells (Fig. 3a) . The phosphorylated MEK1 signal was hardly detected in control cells, but low-level expression of the anchoring protein (by transfection of cells with 0.1 μg of AKAP-Lbc plasmid) enhanced detection of phosphorylated MEK1 (Fig. 3a) . Thus, spatially constraining RAF in the context of the AKAP-Lbc-KSR-1 network favours the relay of signals to MEK. Conversely, high-level expression of AKAP-Lbc (by transfection with 10-fold more plasmid) yielded only a moderate increase in MEK1 phosphorylation (Fig. 3a) . Similar results were obtained when antibodies against phosphorylated ERK were used to monitor the activation state of this kinase ( Supplementary Information, Fig. S3 ). This is consistent with the model that a scaffolding protein, if present in excess of its constituent binding partners, impairs signalling by assembling nonproductive complexes 19−21 . Detection of phosphorylated ERK1/2 by immunofluorescence microscopy functions as an index of ERK-kinase activation in situ 22 .
Phosphorylated ERK1/2 staining was barely detectable in control NIH3T3 fibroblasts (Fig. 3b, d, f) . However, the basal phosphorylated ERK1/2 signal was enhanced in cells that express recombinant AKAPLbc (tagged with GFP for detection in microscopy, Fig. 3c, e, g ). These data suggest that the AKAP-Lbc-KSR-1 network maximizes the relay of signals from RAF to ERK in the resting state. Next, we monitored ERK-activation dynamics on gene silencing of AKAP-Lbc in HEK293 cells. Knockdown of AKAP-Lbc was confirmed by immunoblotting (Fig. 3i, inset) . Real-time imaging of cells expressing EKAR demonstrated that depletion of AKAP-Lbc inhibited the onset, and almost abolished, EGF-dependent ERK activation when compared with cells treated with control siRNA (Fig. 3h, i) . Additional experiments focused on the contribution of anchored PKA in this process. Global disruption of PKA anchoring is often achieved by the delivery of Ht31, an anchoring-inhibitor peptide derived from AKAP-Lbc 23 . Displacement of PKA on treatment of cells with Ht31 delayed the onset of EGF-mediated EKAR FRET (Fig. 3j , red triangles) when compared with controls (Fig. 3j,  black circles) . Thus, AKAP-Lbc-directed PKA phosphorylation of substrates within the network may enhance ERK1/2 signalling. Next, we investigated how AKAP-Lbc associated PKA modulates the ERK1/2 cascade. As an anchoring protein, AKAP-Lbc positions PKA close to important substrates, so potential PKA targets were examined in the AKAP-Lbc-KSR-1 complex. In HEK293 cells, cAMP activates ERK1/2, which was suppressed by approximately 48 ± 9% (n = 3) on pre-treatment of cells with H-89, a pharmacological inhibitor of PKA (Fig. 4a) . Subsequent analysis detected cAMP-responsive phosphorylation of KSR-1 in immunoprecipitated complexes isolated from HEK293 cells (Fig. 4b) . This effect was blocked by PKA inhibition with the PKI 5-24 peptide (Fig. 4b) . A role for AKAP-Lbc was established when the AKAP-Lbc-KSR-1 complex was reconstituted with the recombinant anchoring protein or a PKA anchoring-defective mutant (AKAP-Lbc ∆PKA ). Robust cAMP-responsive phosphorylation of KSR-1 was detected in the presence of AKAP-Lbc (Fig. 4c ). In contrast, near baseline levels of KSR-1 phosphorylation were detected in complexes formed with AKAP-Lbc ∆PKA (Fig. 4c) . Thus, AKAPLbc anchors PKA to favour KSR-1 phosphorylation. KSR-1 contains several phosphorylation sites for basophilic kinases ( Supplementary  Information, Fig. S4 ), including a well-conserved consensus PKA site (-R-R-L-S-) surrounding Ser 838 (Fig. 4d) . Incorporation of 32 P into the KSR-1 S838A mutant was reduced approximately 21 ± 3% (n = 4), compared with a wild-type control (Fig. 4e) . These effects were blocked by PKI (Fig. 4e) . This suggests that AKAP-Lbc positions PKA to phosphorylate Ser 838 on KSR-1. Time (h) Supplementary Information, Fig. S7 .
A more stringent test of this hypothesis was performed with transformed mouse embryonic fibroblast (MEF) cell-lines derived from KSR-1 -/-animals 24 . As a prelude to these studies, co-immunoprecipitation approaches confirmed that the AKAP-Lbc-PKA complex could be isolated from MEFs expressing wild type KSR-1, but not from KSR-1 -/-null cells (Fig. 5a ). Immunofluorescence microscopy confirmed that the distribution of AKAP-Lbc and KSR-1 overlapped in these cells (Supplementary Information Fig. S5 ).
Growth-factor-induced ERK1/2 activation was inhibited in KSR-1
MEFs over a time course of 0-16 min, as assessed by immunoblotting of cell lysates (Fig. 5b, c, red circles) . Rescue experiments confirmed that the normal ERK1/2 activation was restored on viral expression of the wildtype scaffolding protein (Fig. 5b, 5c , blue circles). Importantly, the rate and magnitude of growth-factor-induced ERK1/2 activation was inhibited when rescue experiments were performed with the S838A mutant (Fig. 5b, c, black squares) . Immunoblot controls confirmed that equal levels of total ERK1/2 and AKAP-Lbc were present and that equivalent amounts of KSR-1 were expressed in the rescued cells (Fig. 5b) . Similarly, introduction of KSR-1 supported enhanced ERK activation when the EKAR reporter was used to visualize kinase activity in HEK293 cells (Fig. 5d , e, open squares). However, ERK activation was suppressed in the presence of the KSR-1 S838A mutant (Fig. 5d , e, blue circles). Both these approaches suggest that phosphorylation of Ser 838 on KSR-1 ensures optimal activation of the ERK cascade.
Finally, we investigated the impact of the S838A mutation in KSR-1 on cAMP-responsive activation of ERK1/2. cAMP-responsive phosphorylation of ERK1/2 was inhibited (by approximately 30 ± 5%; n = 4) in cells expressing the KSR-1 S838A mutant, compared with cells expressing wildtype KSR-1 (Fig. 5f, g ). Similar analyses in the MEF lines revealed that cAMP stimulation does not result in ERK1/2 activation in KSR-1 -/-MEFs (Fig. 5h, i) . Immunoblotting of lysates from KSR-1 -/-MEFs that are rescued by re-expression of the wild-type scaffolding protein demonstrates that there is robust ERK1/2 phosphorylation following elevation of cAMP (Fig.  5h, i) . In contrast, cAMP stimulation of ERK1/2 activity was not detected in cells rescued with the S838A mutant (Fig. 5h, i) . Controls confirmed that equal levels of total ERK1/2 and AKAP-Lbc were present and that equivalent amounts of KSR-1 were expressed in the rescued cells (Fig. 5h) . Similar results were obtained when cAMP-responsive ERK1/2 activation was measured over time ( Supplementary Information, Fig. S6 ). Further confirmation of these results was provided by in situ immunofluorescence microscopy of phosphorylated ERK1/2 ( Fig. 5j-u) . These results suggest AKAP-Lbc positions PKA for a preferred role in the phosphorylation of Ser 838 on KSR-1 to ensure activation of the ERK cascade.
We have evaluated how AKAP-Lbc shapes ERK signalling through its interaction with KSR-1. The convergence of AKAP-Lbc and KSR-1 binding partners not only generates pockets of concentrated enzyme activity that amplify mitogenic signals, but also creates a platform for cAMP-responsive modulation of the ERK cascade. Although we have not yet established the stoichiometry of the components in this network, the model presented in Figure 5v depicts AKAP-Lbc as an enhancer of RAF signalling that augments the processive phosphorylation and activation of MEK and ERK. Our biochemical and live-cell imaging experiments support this hypothesis by demonstrating that AKAP-Lbc expression levels affect the rate and amplitude of signal relay through the ERK cascade. A fundamental element of this process is the ability of AKAP-Lbc to secure RAF in proximity to its preferred substrate, MEK.
A customary trait of AKAPs is the ability to compartmentalize the PKA holoenzyme with preferred substrates 23 . Our results confirm and extend this concept by placing AKAP-Lbc at an interface between the cAMP and ERK signalling cascades, and provide a plausible explanation for evidence that indicates PKA subunits co-purify with RAF 25 . PKA phosphorylation of multiple sites on the C-Raf isoform is known to suppress signal relay to MEK 26 . Our evidence that B-Raf and C-Raf copurify with AKAP-Lbc (Fig. 2 and Supplementary Information, Fig. S2 ) may have important ramifications for this process as these isozymes respond differently to cAMP. Therefore, it is tempting to speculate that AKAP-Lbc-KSR-1 networks that incorporate C-Raf may respond differently to cAMP than those that include B-Raf. This model suggests a reasonable, albeit simplistic, explanation for the longstanding conundrum that PKA activation can have both positive and negative effects on ERK activity.
Another notable feature of this work is the discovery that anchored PKA phosphorylates KSR-1 to sustain ERK signalling. These studies focus on a consensus PKA substrate site surrounding Ser 838 that is invariant in mammals and is highly conserved across species down to Drosophila melanogaster and Caenorhabditis elegans (Fig. 4d) . We propose that phosphorylation of this site by PKA or related kinases is necessary to sustain a fully functional ERK signalling network as substitution of Ser 838 with alanine blunts cAMP-and growth factordependent activation of ERK1/2 (Fig. 5) . Phosphorylation of Ser 838 in the resting state may also be favoured because the anchored PKA has preferential access to KSR-1. Thus, AKAP-Lbc may connect PKA to the ERK kinase cascade in several ways. This offers a mechanistic insight into what has long been considered to be an enigmatic cellular process: cAMP-responsive control of cell growth. Recombinant protein production. Plasmids encoding GST fusion proteins of AKAP-Lbc fragments 14 were transformed into BL21(DE3)pLysS bacteria. Protein expression was induced by addition of 1 mM isopropyl-1-thio-β-Dgalactopyranoside and overnight growth at 30 o C. Fusion proteins were either purified in large batches using glutathione-Sepharose (GE Life Sciences), or induced bacteria were frozen in small aliquots and proteins were purified at the time of the experiment. For some experiments, protein was produced in vitro using a T7 TNT kit (Promega).
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Cell staining. NIH3T3 cells and MEFs were cultured on glass coverslips (no. 1.5). Cells were fixed with 4% (v/v) paraformaldehyde in PBS for 20 min at room temperature, permeabilized in PBS (supplemented with 0.2% (w/v) BSA and 0.1% (v/v) Triton X-100) for 10 min, and stained with the appropriate primary antibodies overnight at 4 o C. Cells were washed three times in PBS and incubated with Alexa Fluor conjugated secondary antibodies (1:500) for 2 h at room temperature. Cells were washed again and mounted on glass slides using ProLong antifade media (Invitrogen). Nuclei were stained with DRAQ5 or DAPI (4' ,6-diamidino-2-phenylindole) in the final step before mounting. Cells were imaged with either a Zeiss LSM 510 META or a Zeiss AxioObserver microscope with an Apotome slider.
In vitro phosphorylation. After immunoprecipitation and washing, immunocomplexes were washed once in PKA assay buffer (40 mM Tris at pH 7.5, 10 mM MgOAc, 0.1 mM EGTA and 0.05 mM ATP). Phosphorylation reactions were performed in assay buffer for 10-30 min at 30 °C. Assays were supplemented with PKA C-subunit (0.2 μg) or cAMP (0.1 mM). PKI (10 μM final) was included in some reactions to block kinase activity. Reactions were stopped by addition of 2 × NuPAGE sample buffer (Invitrogen) and were analysed by SDS-PAGE and autoradiography. Peptide arrays were produced by SPOT synthesis with a MultiPep robot (Intavis AG). Membranes were blocked in PKA assay buffer containing 100 μM ATP, and phosphorylated as above. After extensive washing, membranes were dried and exposed to film for autoradiography.
Immunoprecipitated-complex kinase assays. B-Raf activity in immunocomplexes was measured using the Raf kinase assay kit for chemiluminescence detection from Millipore (#17-360). The inhibitors sorafenib (Symansis) and ZM336572 (Tocris) were included where appropriate at 1 μM and 10 μM, respectively.
Mass spectrometry. HEK293 cells were transfected with plasmids expressing Flag-AKAP-Lbc. After lysis, immunocomplexes were isolated using Flag-M2 agarose (Sigma) and separated by SDS-PAGE on 4-12% (w/v) NuPAGE gels (Invitrogen). Gels were stained with GelCode Blue (Thermo-Pierce) and bands were excised. Proteins were identified as described 27 .
FRET measurements. HEK293 cells were cultured on 35-mm dishes with poly-d-lysine coated glass coverslip bottoms (MatTek Corporation). Cells were transfected with plasmids encoding the cerulean (CFP)/venus (vYFP) variants of EKAR cyto and EKAR nuc 16 along with appropriate vectors (see figure  legends) . For siRNA experiments, siRNA oligonucleotides were transfected 1 day before transfection with EKAR constructs. After starving overnight, cells were placed in EKAR recording solution (25 mM HEPES at pH 7.4, 114 mM NaCl, 2.2 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 22 mM NaHCO 3 , 1.1 mM NaH 2 PO 4 and 2 mM glucose). Fluorescence emission was acquired using a DMI6000B inverted microscope (Leica), an EL6000 microscope (fluorescent light source, filter wheel, ultra fast shutter, Leica) and a CoolSnap HQ camera (Photometrics) all controlled by MetaMorph 7.6.4 (Molecular Devices). Dualemission images were obtained simultaneously through a Dual-View image splitter (Photometrics) with S470/30 and S535/30 emission filters and 505 dcxr dichroic mirror (Chroma). Exposure time was 200 ms with an image interval of 20 s. FRET changes within a region of interest were calculated as the ratio of measured fluorescent intensities from two channels (M donor , M indirectAcceptor ) after subtraction of background signal. FRET ratio (YFP/CFP) changes after ERK activation by EGF (0.1 μg ml -1 ) and MEK inhibition by UO126 (10 μM) are normalized to the average FRET ratio value before stimulation. Where indicated, cells were pre-treated with 10 μM st-Ht31 peptide (Promega) for 30 min before FRET recording.
Statistical analyses. Analyses were performed using Graph Pad Prism. All data are expressed as mean ± s.e.m. Differences were examined by one-way analysis of variance (ANOVA) or paired t-test. A P value < 0.05 was considered significant, and a P value < 0.01 was considered very significant.
Pulldowns and immunoprecipitations.
These experiments were performed as in ref. 
